TY - JOUR
T1 - Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial
AU - Diletti, Roberto
AU - Farooq, V
AU - Girasis, Chrysafios
AU - Bektas, Fatma
AU - Onuma, Yoshinobu
AU - Heo, JH
AU - Gkogkas, Bill
AU - van Geuns, Robert Jan
AU - Regar, Evelyn
AU - de Bruyne, B
AU - Dudek, D
AU - Thuesen, L
AU - Chevalier, B
AU - McClean, D
AU - Windecker, S
AU - Whitbourn, RJ
AU - Smits, P
AU - Koolen, J
AU - Meredith, I
AU - Li, XL
AU - Miquel-Hebert, K
AU - Veldhof, S
AU - Garcia Garcia, Hector
AU - Ormiston, JA
AU - Serruys, PWJC (Patrick)
PY - 2013
Y1 - 2013
N2 - Background The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. Methods In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and >= 2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. Results At 2-year angiographic follow-up no differences in late lumen loss (0.29 +/- 0.16 mm vs 0.25 +/- 0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25 +/- 3.47 mm(2) vs 13.09 +/- 3.38 mm(2) p=0.0015), scaffold area (5.76 +/- 0.96 mm(2) vs 6.41 +/- 1.30 mm(2) p=0.0008) and lumen area (5.71 +/- 0.98 mm(2) vs 6.20 +/- 1.27 Conclusions Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels.
AB - Background The long-term results after second generation everolimus eluting bioresorbable vascular scaffold (Absorb BVS) placement in small vessels are unknown. Therefore, we investigated the impact of vessel size on long-term outcomes, after Absorb BVS implantation. Methods In ABSORB Cohort B Trial, out of the total study population (101 patients), 45 patients were assigned to undergo 6-month and 2-year angiographic follow-up (Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). The pre-reference vessel diameter (RVD) was <2.5 mm (small-vessel group) in 41 patients (41 lesions) and >= 2.5 mm (large-vessel group) in 60 patients (61 lesions). Outcomes were compared according to pre-RVD. Results At 2-year angiographic follow-up no differences in late lumen loss (0.29 +/- 0.16 mm vs 0.25 +/- 0.22 mm, p=0.4391), and in-segment binary restenosis (5.3% vs 5.3% p=1.0000) were demonstrated between groups. In the small-vessel group, intravascular ultrasound analysis showed a significant increase in vessel area (12.25 +/- 3.47 mm(2) vs 13.09 +/- 3.38 mm(2) p=0.0015), scaffold area (5.76 +/- 0.96 mm(2) vs 6.41 +/- 1.30 mm(2) p=0.0008) and lumen area (5.71 +/- 0.98 mm(2) vs 6.20 +/- 1.27 Conclusions Similar clinical and angiographic outcomes at 2-year follow-up were reported in small and large vessel groups. A significant late lumen enlargement and positive vessel remodelling were observed in small vessels.
U2 - 10.1136/heartjnl-2012-302598
DO - 10.1136/heartjnl-2012-302598
M3 - Article
C2 - 23118346
SN - 1355-6037
VL - 99
SP - 98
EP - 105
JO - Heart
JF - Heart
IS - 2
ER -